<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To compare the effect on glycemic control and <z:mp ids='MP_0005456'>weight gain</z:mp> of repaglinide versus <z:chebi fb="0" ids="6801">metformin</z:chebi> combined with bedtime <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 80 subjects treated with 850 or 1,000 mg t.i.d. <z:chebi fb="0" ids="6801">metformin</z:chebi> combined with bedtime <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin were randomized to 13 weeks of open-label treatment with 4 mg t.i.d. repaglinide (n = 39) or <z:chebi fb="0" ids="6801">metformin</z:chebi> (dose unchanged) (n = 41) </plain></SENT>
<SENT sid="2" pm="."><plain>Insulin dose was titrated at the clinician's discretion, aiming for a fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (FBG) &lt; or =6.0 mmol/l </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Baseline age, <z:mp ids='MP_0002055'>diabetes</z:mp> duration, insulin requirement, weight, BMI, FBG, and HbA(1c) (<z:mp ids='MP_0002055'>Diabetes</z:mp> Control and Complications Trial-aligned assay, <z:mpath ids='MPATH_458'>normal</z:mpath> range 4.6-6.2%) were similar </plain></SENT>
<SENT sid="4" pm="."><plain>Glycemic control improved (nonsignificantly) with insulin/<z:chebi fb="0" ids="6801">metformin</z:chebi> by (mean) 0.4%, from 8.4 to 8.1% (P = 0.09) but deteriorated with insulin/repaglinide by (mean) 0.4%, from 8.1 to 8.6% (P = 0.03; P = 0.005 between groups) </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0005456'>Weight gain</z:mp> was less with insulin/<z:chebi fb="0" ids="6801">metformin</z:chebi>: 0.9 +/- 0.4 kg (means +/- SE) (P = 0.01) versus 2.7 +/- 0.4 kg (P &lt; 0.0001) (P = 0.002 between groups) </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:mp ids='MP_0002055'>Diabetes</z:mp> Treatment Satisfaction Questionnaire score (potential range 0 [minimum] to 36 [maximum]) increased from 32.4 +/- 0.8 to 34.1 +/- 0.5 (P = 0.01) with insulin/<z:chebi fb="0" ids="6801">metformin</z:chebi> but decreased from 32.5 +/- 0.9 to 29.1 +/- 1.3 (P &lt; 0.002) with insulin/repaglinide </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Combined with bedtime <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin, <z:chebi fb="0" ids="6801">metformin</z:chebi> provides superior glycemic control to repaglinide with less <z:mp ids='MP_0005456'>weight gain</z:mp> and improved <z:mp ids='MP_0002055'>diabetes</z:mp> treatment satisfaction </plain></SENT>
</text></document>